NVCT vs NXTC

Nuvectis Pharma, Inc. vs NextCure, Inc. — Valuation Comparison 2026

NVCT

Biotechnology
Nuvectis Pharma, Inc.
Quality
3.8
out of 10
Value Trap
18
SAFE
Price
$10.19
Last close
Models
6/13
Active
VS

NXTC

Biotechnology
NextCure, Inc.
Quality
4.5
out of 10
Value Trap
24
SAFE
Price
$6.40
Last close
Models
7/13
Active

Model-by-Model Comparison

ModelType NVCT Fair ValueNVCT Upside NXTC Fair ValueNXTC Upside
Bayesian DCF Intrinsic $3.24 -68.2% $3.41 -46.7%
First Chicago Scenario $•••.•• ••.•% $•••.•• ••.•%
ML-RIV Intrinsic $18.39 +187.4%
Dynamic NAV Asset-Based $1.15 -88.7% $27.17 +324.5%
PWERM Option-Based $•••.•• ••.•% $•••.•• ••.•%
Sentiment SOTP Hybrid $•••.•• ••.•% $•••.•• ••.•%
CUCE Ensemble Ensemble $•••.•• ••.•% $•••.•• ••.•%
🔒

Unlock Full 13-Model Comparison

Access all valuation models for NVCT vs NXTC — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

NVCT vs NXTC — Which Stock Is More Undervalued?

NXTC scores higher with a 4.5/10 quality rating vs NVCT's 3.8/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing Nuvectis Pharma, Inc. (NVCT) and NextCure, Inc. (NXTC) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

NVCT currently trades at $10.19 with a QOC of 3.8/10, while NXTC trades at $6.40 with a QOC of 4.5/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).